What Is A1 Milk? Why It Dominates Commercial Dairy, and What That Means for You
The milk sold in most Indian cities contains A1 beta-casein, a protein variant that did not exist in Indian dairy for most of history. Here is where it came from, what it does in the gut, and who it affects.
A1 milk is milk containing A1 beta-casein, a protein variant found in most modern commercial dairy breeds, predominantly Holstein Friesian and Jersey cattle. During digestion, A1 beta-casein breaks down and releases a peptide called BCM-7 that causes gut inflammation in sensitive individuals. Most commercial milk sold in India today contains A1 beta-casein because India's organised dairy sector expanded using high-yield European breeds that carry this variant.
Most people who drink milk every day have never heard of A1 beta-casein. They have not needed to. The milk came, they drank it, and for many of them, it worked fine. For a significant minority, it did not work fine at all, and they spent years attributing the problem to lactose without ever questioning the protein.
Understanding A1 milk starts with understanding that "regular milk" is not a natural category. It is the product of specific breeding decisions made over the last century, decisions driven by yield rather than digestibility, that changed the protein composition of the milk supply in ways that were not understood at the time.
The OriginWhere A1 Beta-Casein Came From
All cattle originally produced A2 beta-casein. The protein existed in its ancestral form across all bovine populations until a spontaneous mutation occurred in northern European cattle approximately 8,000 years ago. This mutation changed a single amino acid in the beta-casein chain at position 67, substituting histidine for the original proline. The resulting variant is A1 beta-casein.
The mutation did not cause visible health problems in the cattle themselves and had no observable impact on milk volume or composition by any measure available at the time. It spread through northern European bovine populations and became dominant in the breeds that would later be selected for maximum dairy yield: Holstein Friesian in the Netherlands and Germany, Ayrshire in Scotland, British Friesian in England.
When colonial and post-colonial agricultural programmes spread these high-yield European breeds globally through the twentieth century, the A1 mutation went with them. India's dairy expansion under Operation Flood and subsequent policy programmes introduced Holstein Friesian genetics into Indian herds at scale, creating the crossbred population that now supplies most of India's organised dairy sector.
The Digestion Problem With A1 Beta-Casein
During digestion, the enzyme dipeptidyl peptidase IV cleaves A1 beta-casein at position 67, where histidine creates a flexible point in the protein chain. This cleavage releases a seven-amino-acid peptide called BCM-7 (beta-casomorphin-7).
BCM-7 is an opioid peptide. It binds to mu-opioid receptors in the gut wall. In people with high opioid receptor sensitivity, this binding slows gut motility, increases mucus secretion, and triggers a local inflammatory response that produces bloating, cramping, loose stools, and in some people, increased mucus or phlegm after consuming dairy. These symptoms are clinically identical to lactose intolerance. Most people experiencing them have assumed that is what they have.
A2 beta-casein has proline at position 67 instead of histidine. Proline creates a rigid structural kink that prevents the enzyme from cleaving the chain at that point. No cleavage means no BCM-7. No BCM-7 means no opioid receptor binding and no inflammatory gut response.
Both BCM-7 sensitivity and lactose intolerance produce bloating, cramping, and loose stools after consuming milk. The timing is similar. The resolution when dairy is removed is similar. The key difference: lactase supplements resolve lactose intolerance symptoms but have no effect on BCM-7 sensitivity. If your dairy symptoms persist after taking a lactase enzyme, BCM-7 sensitivity is the more likely cause.
BCM-7 Sensitivity Is Not Universal
BCM-7 production from A1 beta-casein digestion is universal. Every person who digests A1 milk produces the peptide. BCM-7 sensitivity is not universal. The symptoms depend on opioid receptor expression in the gut wall, which is genetically determined and varies between individuals.
People with lower mu-opioid receptor sensitivity in their gut produce BCM-7 and feel nothing noteworthy. Their gut processes the peptide without a significant inflammatory response. They can drink A1 milk indefinitely without digestive discomfort.
People with higher sensitivity produce BCM-7 and experience the gut symptoms described above. For this population, the practical solution is consuming dairy that does not produce BCM-7, which means A2 milk from A2A2 genetically verified animals.
Why This Matters Now More Than Before
For most of Indian dairy history, the milk consumed in households came from indigenous cattle and buffalo, all of which produce A2 beta-casein naturally. The digestive complaints now associated with "milk" were far less prevalent when the milk supply was predominantly indigenous.
India's shift to crossbred HF cattle for organised dairy production brought A1 genetics into the supply at scale. The average urban Indian household now receives milk from animals whose protein genetics would have been absent from Indian dairy fifty years ago. The rise in reported dairy sensitivity across Indian urban populations over this period is plausibly connected to this change, though isolating this single factor in epidemiological data is difficult.
The growth of the A2 dairy market in India reflects a partial reversal of that trend. Farmers and brands returning to indigenous breeds are, among other things, returning to the protein genetics that Indian consumers were accustomed to for centuries.
A1 milk is not dangerous. For the majority of consumers who digest it without symptoms, it provides good nutrition at a lower cost than premium alternatives. The peer-reviewed research on BCM-7 documents a real digestive mechanism affecting a real population, not a universal health risk from A1 milk. Characterising A1 milk as universally harmful overstates what the science shows.
The alternative to A1 milk already exists in India.
India's indigenous dairy breeds have always produced A2 milk. Shunya's network puts the infrastructure behind them so the supply is consistent, traceable, and available year-round.